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osting by EAbstract Objective: To evaluate the efﬁcacy and tolerability of Levetiracetam (LEV) as an
adjunctive therapy in pediatric patients with different generalized epilepsies.
Design: Chart review of 22 consecutive children age 4–19 years who were treated with LEV for at
least 1 year was observed retrospectively. The mean dose rang of LEV was from 250 to 2000 mg.
Data were collected on epilepsy type, seizure frequency, concomitant antiepileptic drug and adverse
effect.
Results: Of the 22 patient reviewed, 13 (59%) were boys and 9 (41%) were girls. Predominant sei-
zure types were generalized tonic–clonic seizures 13 (59%) and tonic seizure 6 (27%). Other seizure
types included myoclonic seizures 2 (9%) and focal seizure 3 (5%). The results showed 10 (45%)
had become free of seizure for almost 7 months to 1 year. Eight of these 10 patients (80%) had nor-
malized EEG. Seizure frequency was reduced in 9 (41%) patients and 3 (14%) patients still had sei-
zure. No side effects were reported related to LEV treated patients except for 1 patient.
Conclusion: Our results conﬁrm that LEV may be an effective adjunctive therapy in treatment of
childhood epilepsy, especially tonic–clonic seizure, with possible no evident side effect.
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lsevier1. Introduction
Epilepsy is the most common serious neurological disorder
and is one of the most prevalent noncommunicable diseases
in the world (Scott et al., 2001). Control of abnormal neuronal
activity with antiepileptic drugs (AEDs) is accomplished by
elevating the threshold of neurons to electrical or chemical
stimuli or by limiting the propagation of the seizure discharge
from its origin (Gidal and Garnett, 2005). Choice of an AED
for the treatment of epilepsy in infants and children depends
not only on the efﬁcacy of the agent but also in safety, impact
on behavior and learning, and existing patient co-morbidities
(Sankar, 2005).
Levetiracetam (LEV), an antiepileptic drug, has become
widely used in the treatment of several types of epilepsy. It is
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myoclonic, and/or primary generalized tonic–clonic seizures
(Crest et al., 2004; Kwan et al., 2010). In children, Levetirace-
tam (LEV) is an antiepileptic drug that is approved for use as
adjunct treatment for partial epilepsy in patients aged 4 years
and older, as well as for juvenile myoclonic epilepsy in patients
aged 12 years and older (Major et al., 2008). Initial perfor-
mance in standard animal screening models proved disap-
pointing (Klitgaard et al., 1998), but the drug’s success in
clinical trials and humans have led some to question whether
standard screening models should be reevaluated. For clini-
cians, LEV was attractive because of its lack of hepatic metab-
olism, minimal drug interactions, activity against several
seizure types, and ability to start an effective dose on day
one (Privitera and Cavitt, 2008).
The exact antiepileptic mechanism of LEV is unknown.
However, the drug binds to a synaptic vesicle protein, SV2A,
which is believed to impede nerve conduction across synapses
(Lynch et al., 2004; Rogawski, 2006; Abou-Khalil, 2008). The
aim of this study is to evaluate retrospectively the effectiveness
of LEV in different types of pediatric epilepsy and its possible
side effects.
2. Methods
A retrospective chart review was performed at King Abdulaziz
University Hospital (KAUH), Jeddah, Saudi Arabia on chil-
dren with epilepsy who were treated with LEV (Keppra)
from 2005 to 2010. The study was done after approval from
KAUH review board and it was conducted to assess the effec-
tiveness and tolerability of LEV as adjunctive therapy in
children.
The study was carried out on children diagnosed with epi-
lepsy based on clinical evaluation and electroencephalogram
(EEG) abnormalities. All children with associated conditions
as developmental delay, brain malformations, and inborn er-
ror of metabolism were excluded from the study. The initial
study group of 35 was reduced to 22 as a result of insufﬁcient
data available in 10 patients and inability of the hospital for
providing the drug in 3 patients. Children who were treated
with the mean dose range of LEV from 250 to 2000 mg and
aged from 4 to 19 years were identiﬁed retrospectively. Data
were collected on patient age, gender, seizure type, other anti-
epileptic drugs concomitantly used with LEV, and ﬁnally,
change in seizure frequency before and after adding LEV.
The starting dose regime of LEV was always introduced
10–15 mg/kg/day once daily. Further dose increases were
undertaken in 10 mg/kg/day increments every 2 weeks. The
drug was available in tablet form only (250 and 500 mg tab-
lets). The efﬁcacy of LEV treatment with respect to seizure
control was classiﬁed as <25% seizure reduction, P25%
and <50% seizure reduction, P50% and <75% seizure
reduction, P75% seizure reduction, and seizure freedom. Ad-
verse effects were obtained retrospectively from the medical re-
cord ﬁles. Data of the study were analyzed descriptively.
3. Results
The results of the study and the patient data are shown in
Table 1. Of the 22 patient reviewed, 13 (59%) were boys and
9 (41%) were girls. The average age was 3–19 years(mean = 10 years). With the exception of 1 patient, all have re-
ceived concomitant antiepileptic medication. The most com-
mon antiepileptic drugs included topiramate, valproate,
lamotrigine, clonazepam, vigabatrin, carbamazepine and
phenobarbital.
Predominant seizure types were generalized tonic–clonic
seizures 13 (59%) and tonic seizure 6 (27%). Other seizure
types included myoclonic seizures 2 (9%) and focal seizure 3
(5%).
The mean dosage range of LEV was 250–2000 mg and the
duration of treatment ranged from 1 to 5 years.
Of the 22 patients, 10 (45%) had become free of seizure for
almost 7 months to 1 year especially in those with tonic–clonic
convulsions. Eight of these 10 patients (80%), had normalized
EEG. Seizure frequency was reduced in 9 (41%) patients and 3
(14%) patients still had seizure (Fig. 1). There was no promi-
nent side effect related to LEV except for one patient (5%)
who was coadministered vigabatrin where the patient has re-
corded change in attitude and behavior with loss of appetite.4. Discussion
Epilepsy is a common chronic disorder that requires long-term
antiepileptic drug therapy. Approximately one half of patients
fail the initial antiepileptic drug and about 35% are refractory
to medical therapy, highlighting the continued need for more
effective and better tolerated drugs (Abou-Khalil, 2008).
LEV has been demonstrated effective as adjunctive therapy
for refractory partial-onset seizures, primary generalized to-
nic–clonic seizures, and myoclonic seizures (Major et al.,
2008; Abou-Khalil, 2008).
The current study showed that seizure frequency was re-
duced in 41% of pediatric patients who used LEV. Moreover,
45% of the patients had become seizure free for almost
7 months to 1 year with normalization of EEG in 80% of these
patients. This ﬁnding is consistent with a previous study which
revealed that LEV appeared to be effective in decreasing epi-
leptiform EEG abnormalities (Specchio et al., 2008). Most of
the seizure types were found to be of tonic–clonic type. Preli-
minary evidence by Verrotti et al. (2008) revealed that LEV
may be effective for treating 32 adolescent patients with newly
diagnosed Juvenile myoclonic epilepsy (JME). Verrotti and his
colleagues found at 6-month evaluation: 15 patients were sei-
zure free; 14 patients were responders (>50% reduction in sei-
zures); and three patients had marginal effects (<50%
reduction of seizures). At 12-month evaluation: 29 patients
were seizure free; three patients were responders with no re-
ported adverse events. Moreover, Specchio et al. (2008) sup-
ports a ﬁrst-line role for LEV in the treatment of JME.
Consistently, Stephen et al. (2011) found that seizure freedom
was achieved in around half adult patients on a median LEV
dose of 1000 mg/day. On the other hand, most previous studies
of children treated with LEV demonstrated seizure-freedom
rates from 5% to 23%, with total duration of seizure freedom
ranging from 1 to 38 months (Wheless and Ng, 2002; Lagae
et al, 2003). Koukkari and Guarino (2004) studied the effect
of LEV in childhood seizure disorders that included 50 pa-
tients with partial and generalized seizures. The study showed
12 hadP75% seizure reduction, 3 hadP50% and <75% sei-
zure reduction, 8 had P25% and <50% seizure reduction,
and 27 had <25% seizure reduction. In addition, Perry and
Table 1 Patient data for those who received levetiracetam (LEV, Keppra) as adjuvant therapy.
ID Age
(year)/
gender
Type of seizure Concomitant medications Mean LEV
dose (mg)
Duration
useof
LEV (year)
Seizure frequency after LEV Side eﬀect
1 4/F Generalized tonic clonic Topiramate 125 mg OD 250 2.5 Seizure free for more than year
with normalized EEG
None
Clonazepam
2 Drops BID
Vit B6 40 mg BID
Valproic acid 1.5 ml BID
2 4/M Tonic convulsion Topiramate 25 mg OD 500 1 Seizure free for more than
10 months with normalized
EEG
None
3 4/F Tonic convulsion Clonazepam 2 drops TID 250 1 Decreased frequency of seizure None
Topiramate 25 mg BID
4 4/M Tonic convulsion Lamotirgine 10 mg BID 250 2 Still has seizures None
Topiramate 25 mg BID
5 5/M Myoclonic seizures Valproic acid 150 BID 500 2 Decreased frequency of seizure None
6 6/F Generalized tonic clonic Valproic acid 15 mg BID 500 1 Seizure free with normalized
EEG
None
Clonazepam 2 drops BID
7 6/F Myoclonic seizures Topiramate 25 mg am 250 2 Still have seizure Change in
attitude
and
behavior
and loss of
appetite
50 mg pm
Vigabatrin 250 mg BID
8 6/M Tonic convulsion Valproic acid 5 ml BID 250/500 1 Decreased frequency of seizure
(but still have some attacks
every 1–2 weeks)
None
Carbamazepine 25 ml BID
9 9/M Generalized tonic clonic Lamotirgine 50 mg BID 750 2 Seizure free for more than
1 year with normalized EEG
None
Carbamazepine 3 ml TID
10 9/M Generalized tonic clonic Topiramate 100 BID 500 2.5 Seizure free for 7 months with
normalized EEG
None
11 9/M Generalized tonic clonic Topiramate 100 mg BID 1000 3 Seizure free for 1 year with
normalized EEG
None
12 10/M Tonic convulsion Lamotirgine 50 mg BID 250 5 Seizure free for 8 months None
Topiramate 50 mg BID
13 10/M Generalized tonic clonic Non 500 2 Still have seizure None
14 11/F Generalized tonic clonic Carbamazepine 300 mg BID 1000 1.5 Seizure free for more than
1 year with normalized EEG
None
Topiramate 75 mg BID
15 12/F Rt side focal convulsions
Convulsions
Topiramate 100 mg am 1000 1 Decreased frequency of seizure
(one seizure per month)
None
200 mg pm
Carbamazepine 400 mg BID
16 14/F Generalized tonic clonic Carbamazepine 400 mg am 1000 1 Decreased frequency of seizure None
200 mg pm
17 14/F Generalized tonic clonic Lamotirgine 75 mg BID 1000 5 Decreased frequency of seizure None
Phenobarbital 50 mg BID
18 18/M Generalized tonic clonic Valproic acid 500 mg BID 500 1.5 Decreased frequency of seizure None
Lamotirgine 100 mg BID
19 18/M Generalized tonic clonic Lamotirgine 50 mg BID 1000 4 Seizure free for more than
8 months
None
Valproic acid 5 ml BID
20 18/M Generalized tonic clonic Valproic acid 500 mg BID 2000 2 Decreased frequency of seizure None
Lamotirgine 100 mg BID
21 18/F Tonic convulsion Topiramate 125 mg BID 1000 3 Decreased frequency of seizure None
Valproic acid 500 mg BID
22 19/M Generalized tonic clonic Topiramate 100 mg BID 1000 2 Seizure free for more than
8 month with normalized EEG
None
Efﬁcacy and safety of levetiracetam in pediatric epilepsy 83Benatar (2007) showed that 57% of the patients experienced at
least some duration of seizure freedom, with a median dura-
tion of clinical response of 8.9 months. 80% of those patients
who became seizure free maintained seizure freedom in excess
of 6 months. This ﬁnding was in accordance with the current
study that showed 45% of patients had become seizure free
for almost 7 months to 1 year.No adverse events associated with LEV were documented
in this study except for one child where he experienced change
in attitude and behavior and loss of appetite which may be
attributed to either vigabatrin or LEV. Major et al., suggested
the possible efﬁcacy of pyridoxine supplementation in the
treatment of LEV-induced behavioral side effects (Major
et al., 2008). On the other hand, the observed adverse event
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Figure 1 Patient outcome treated with levetiracetam (LEV).
84 A.A. Elberry et al.proﬁle of LEV among pediatric patients in previous studies
were mainly related to the central nervous system, and the
most frequent was somnolence, asthenia, dizziness, and behav-
ioral difﬁculties (Shorvon et al, 2000; Ben-Menachem and Fal-
ter, 2000; Glauser et al., 2002; Sirsi and Safdieh, 2007).
5. Conclusion
In conclusion, the present study showed that LEV may be an
effective adjunctive therapy in treatment of childhood epilepsy,
especially tonic–clonic seizure, with possible no evident side
effect.
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